Singapore-based ASLAN Pharmaceuticals aims to raise $86 million in a U.S. IPO. The Taipei-listed firm has a pipeline of late-stage treatment candidates for various cancers that are prevalent in Asia. Management’s collaborative efforts and the company’s …
( read original story …)
Search your Hotel